-
Something wrong with this record ?
The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line
Kovár L, Strohalm J, Chytil P, Mrkvan T, Kovár M, Hovorka O, Ulbrich K, Ríhová B.
Language English Country United States
- MeSH
- Acrylamides analysis pharmacology chemistry MeSH
- Apoptosis genetics MeSH
- Genes, cdc MeSH
- Doxorubicin analysis pharmacology chemistry MeSH
- Gene Expression drug effects MeSH
- Financing, Organized MeSH
- Phosphorylation MeSH
- Inhibitory Concentration 50 MeSH
- Caspase 3 metabolism MeSH
- Lymphoma, T-Cell chemistry metabolism MeSH
- Mitogen-Activated Protein Kinase Kinases antagonists & inhibitors metabolism MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- NF-kappa B metabolism MeSH
- Cell Proliferation drug effects MeSH
- Flow Cytometry MeSH
- Cell Survival MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
Doxorubicin is one of the most potent anti-tumor drugs with a broad spectrum of use. To reduce its toxic effect and improve its pharmacokinetics, we conjugated it to an HPMA copolymer carrier that enhances its passive accumulation within solid tumors via the EPR effect and decreases its cytotoxicity to normal, noncancer cells. In this study, we compared the antiproliferative, pro-survival, and death signals triggered in EL-4 cancer cells exposed to free doxorubicin and doxorubicin conjugated to a HPMA copolymer carrier via either enzymatically (PK1) or hydrolytically (HYD) degradable bonds. We have previously shown that the intracellular distribution of free doxorubicin, HYD, and PK1 is markedly different. Here, we demonstrated that these three agents greatly differ also in the antiproliferative effect and cell death signals they trigger. JNK phosphorylation sharply increased in cells treated with HYD, while treatment with free doxorubicin moderately decreased and treatment with PK1 even strongly decreased it. On the other hand, treatment with free doxorubicin greatly increased p38 phosphorylation, while PK1 and HYD increased it slightly. PK1 also significantly increased ERK phosphorylation, while both the free doxorubicin and HYD conjugate slightly decreased it. Long-term inhibition of JNK significantly increased both proliferation and viability of EL-4 cells treated with free doxorubicin, showing that the JNK signaling pathway could be critical for mediating cell death in EL-4 cells exposed to free doxorubicin. Both activation of caspase 3 and decreased binding activity of the p50 subunit of NFkappaB were observed in cells treated with free doxorubicin and HYD, while no such effects were seen in cells incubated with PK1. Analysis of the expression of genes involved in apoptosis and regulation of the cell cycle demonstrated that free doxorubicin and HYD have very similar mechanisms of action, while PK1 has very different characteristics.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10000660
- 003
- CZ-PrNML
- 005
- 20111210154737.0
- 008
- 100113s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kovář, Lubomír $7 xx0126758
- 245 14
- $a The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line / $c Kovár L, Strohalm J, Chytil P, Mrkvan T, Kovár M, Hovorka O, Ulbrich K, Ríhová B.
- 314 __
- $a Department of Immunology and Gnotobiology, Institute of Microbiology ASCR, v.v.i., VídenskA 1083, 142 20 Prague 4, Czech Republic. lkovar@biomed.cas.cz
- 520 9_
- $a Doxorubicin is one of the most potent anti-tumor drugs with a broad spectrum of use. To reduce its toxic effect and improve its pharmacokinetics, we conjugated it to an HPMA copolymer carrier that enhances its passive accumulation within solid tumors via the EPR effect and decreases its cytotoxicity to normal, noncancer cells. In this study, we compared the antiproliferative, pro-survival, and death signals triggered in EL-4 cancer cells exposed to free doxorubicin and doxorubicin conjugated to a HPMA copolymer carrier via either enzymatically (PK1) or hydrolytically (HYD) degradable bonds. We have previously shown that the intracellular distribution of free doxorubicin, HYD, and PK1 is markedly different. Here, we demonstrated that these three agents greatly differ also in the antiproliferative effect and cell death signals they trigger. JNK phosphorylation sharply increased in cells treated with HYD, while treatment with free doxorubicin moderately decreased and treatment with PK1 even strongly decreased it. On the other hand, treatment with free doxorubicin greatly increased p38 phosphorylation, while PK1 and HYD increased it slightly. PK1 also significantly increased ERK phosphorylation, while both the free doxorubicin and HYD conjugate slightly decreased it. Long-term inhibition of JNK significantly increased both proliferation and viability of EL-4 cells treated with free doxorubicin, showing that the JNK signaling pathway could be critical for mediating cell death in EL-4 cells exposed to free doxorubicin. Both activation of caspase 3 and decreased binding activity of the p50 subunit of NFkappaB were observed in cells treated with free doxorubicin and HYD, while no such effects were seen in cells incubated with PK1. Analysis of the expression of genes involved in apoptosis and regulation of the cell cycle demonstrated that free doxorubicin and HYD have very similar mechanisms of action, while PK1 has very different characteristics.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a akrylamidy $x analýza $x farmakologie $x chemie $7 D000178
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a apoptóza $x genetika $7 D017209
- 650 _2
- $a kaspasa 3 $x metabolismus $7 D053148
- 650 _2
- $a CDC geny $7 D018816
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a doxorubicin $x analýza $x farmakologie $x chemie $7 D004317
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a exprese genu $x účinky léků $7 D015870
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a lymfom T-buněčný $x chemie $x metabolismus $7 D016399
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a mitogenem aktivované proteinkinasy kinas $x antagonisté a inhibitory $x metabolismus $7 D020929
- 650 _2
- $a NF-kappa B $x metabolismus $7 D016328
- 650 _2
- $a fosforylace $7 D010766
- 700 1_
- $a Strohalm, Jiří $7 xx0109134
- 700 1_
- $a Chytil, Petr. $7 _AN032430
- 700 1_
- $a Mrkvan, Tomáš $7 xx0062385
- 700 1_
- $a Kovář, Marek $7 xx0114168
- 700 1_
- $a Hovorka, Ondřej, $d 1971- $7 xx0062705
- 700 1_
- $a Ulbrich, Karel, $d 1947- $7 jo2004259877
- 700 1_
- $a Říhová, Blanka, $d 1942- $7 jo20000073671
- 773 0_
- $w MED00006454 $t Bioconjugate chemistry $g Roč. 18, č. 3 (2007), s. 894-902 $x 1043-1802
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20090310084605 $b ABA008
- 991 __
- $a 20100113144938 $b ABA008
- 999 __
- $a ok $b bmc $g 703389 $s 565828
- BAS __
- $a 3
- BMC __
- $a 2007 $b 18 $c 3 $d 894-902 $i 1043-1802 $m Bioconjugate chemistry $x MED00006454
- LZP __
- $a 2010-b1/ipme